Solid Biosciences (SLDB) Assets (2017 - 2026)

Solid Biosciences has reported Assets for 10 years, with the latest figure at $422.9 million in Q1 2026.

• Quarterly Assets rose 22.97% year-over-year to $422.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $422.9 million (up 22.97% YoY) and the FY2025 annual result came in at $232.5 million, up 23.26% from the prior year.
• Assets grew to $422.9 million in Q1 2026 per SLDB's latest filing, from $232.5 million in the prior quarter.
• Over five years, Assets peaked at $422.9 million in Q1 2026 and troughed at $164.9 million in Q4 2023.
• A 5-year average of $241.6 million and a median of $229.6 million in 2023 frame the typical range for Assets.
• The sharpest annual moves came in 2023 and 2025: Assets plunged 36.62% in 2023, then soared 38.29% in 2025.
• Over 5 years, Assets stood at $260.3 million in 2022, then slumped by 36.62% to $164.9 million in 2023, then rose by 14.38% to $188.7 million in 2024, then increased by 23.26% to $232.5 million in 2025, then soared by 81.86% to $422.9 million in 2026.
• According to Business Quant data, Assets over the past three periods registered $422.9 million, $232.5 million, and $273.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.